A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults with Lewy Body Dementia Psychosis (LBDP)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521710-25-00

Acronym

ACP-204

Enrollment

Registered

2025-10-29

Start date

2025-12-04

Completion date

Unknown

Last updated

2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lewy Body Dementia Psychosis (LBDP)

Brief summary

Change from Baseline in SAPS-LBDP total score at Week 6

Interventions

DRUGPlacebo for ACP-204 capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from Baseline in SAPS-LBDP total score at Week 6	—

Countries

Bulgaria, Czechia, France, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026